Diagnosis of Heart Failure with Preserved Ejection Fraction

Heart Failure Clinics

Volumn 10, Issue 3, 2014, Pages 399-406

  Wachter, Rolf ^a   Edelmann, Frank ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Biomarkers; Diagnosis; Diastolic dysfunction; Diastolic heart failure; Echocardiographic; Heart failure with preserved ejection fraction

Indexed keywords

SODIUM CHLORIDE;

CHRONIC KIDNEY DISEASE; CHRONIC LUNG DISEASE; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DYSPNEA; EXERCISE TOLERANCE; FATIGUE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITAL PATIENT; HUMAN; HYPERVOLEMIA; PAROXYSMAL DYSPNEA; PHYSICAL EXAMINATION; PULMONARY HYPERTENSION; REVIEW; AGED; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MALE; MIDDLE AGED; PHYSIOLOGIC MONITORING; PHYSIOLOGY; PRACTICE GUIDELINE; PROCEDURES; PROGNOSIS; REFERENCE VALUE; RISK ASSESSMENT; SURVIVAL RATE; SYNDROME; THORAX RADIOGRAPHY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIAC CATHETERIZATION; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER, COLOR; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PHYSICAL EXAMINATION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RADIOGRAPHY, THORACIC; REFERENCE VALUES; RISK ASSESSMENT; STROKE VOLUME; SURVIVAL RATE; SYNDROME; VENTRICULAR FUNCTION, LEFT;

EID: 84903395723     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2014.04.010     Document Type: Review

References (29)

1. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. NEngl J Med 2006, 355:251-259.
2. Topol E.J., Traill T.A., Fortuin N.J. Hypertensive hypertrophic cardiomyopathy of the elderly. NEngl J Med 1985, 312:277-283.
3. Paulus W.J., Tschöpe C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28:2539-2550.
4. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869.
5. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol 2013, 62:e147-e239.
6. Rigolli M., Whalley G.A. Heart failure with preserved ejection fraction. JGeriatr Cardiol 2013, 10:369-376.
7. Ho J.E., Gona P., Pencina M.J., et al. Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J 2012, 33:1734-1741.
8. Stahrenberg R., Edelmann F., Mende M., et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 2010, 12:1309-1316.
9. Becher P.M., Lindner D., Fluschnik N., et al. Diagnosing heart failure with preserved ejection fraction. Expert Opin Med Diagn 2013, 7:463-474.
10. Westermann D., Kasner M., Steendijk P., et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008, 117:2051-2060.
11. Wachter R., Schmidt-Schweda S., Westermann D., et al. Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure. Eur Heart J 2009, 30:3027-3036.
12. Mohammed S.F., Borlaug B.A., Roger V.L., et al. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail 2012, 5:710-719.
13. Paulus W.J., Tschöpe C. Anovel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. JAm Coll Cardiol 2013, 62:263-271.
14. Quiroz R., Doros G., Shaw P., et al. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction reduced left ventricular ejection fraction in an urban cohort. Am J Cardiol 2014, 113:691-696.
15. Weber T., Wassertheurer S., ÓRourke M.F., et al. Pulsatile hemodynamics in patients with exertional dyspnea. Potentially of value in the diagnostic evaluation of suspected heart failure with preserved ejection fraction. JAm Coll Cardiol 2013, 61:1874-1883.
16. Lam C.S., Roger V.L., Rodeheffer R.J., et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. JAm Coll Cardiol 2009, 53:1119-1126.
17. Galiè N., Hoeper M.M., Humbert M., ESC Committee for Practice Guidelines (CPG), et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-2537.
18. Simonneau G., Gatzoulis M.A., Adatia I., et al. Updated clinical classification of pulmonary hypertension. JAm Coll Cardiol 2013, 62(Suppl 25):D34-41.
19. Robbins I.M., Hemnes A.R., Pugh M.E., et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 2014, 7:116-122.
20. Fujimoto N., Borlaug B.A., Lewis G.D., et al. Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation 2013, 127:55-62.
21. Hoeper M., Barberà J.A., Channick R.N., et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. JAm Coll Cardiol 2009, 54:S85-S96.
22. Van Empel V.P., Kaye D.M. Integration of exercise evaluation into the algorithm for evaluation of patients with suspected heart failure with preserved ejection fraction. Int J Cardiol 2013, 168:716-722.
23. Smith D.H., Thorp M.L., Gurwitz J.H., et al. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study. Circ Cardiovasc Qual Outcomes 2013, 6:333-342.
24. Wang A.Y., Wang M., Lam C.W., et al. Heart failure with preserved or reduced ejection fraction in patients treated with peritoneal dialysis. Am J Kidney Dis 2013, 61:975-983.
25. Gopal D.M., Kommineni M., Ayalon N., et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. JAm Heart Assoc 2012, 1:e000760.
26. Desai A.S., Lewis E.F., Li R., et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011, 162:966-972.
27. Pitt B., Pfeffer M.A., Assmann S.F., et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. NEngl J Med 2014, 370:1383-1392.
28. Edelmann F., Wachter R., Schmidt A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013, 309:781-791.
29. Henkel D.M., Redfield M.M., Weston S.A., et al. Death in heart failure: a community perspective. Circ Heart Fail 2008, 1:91-97.